EndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company's products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company's imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company's single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Imaging Systems
- Sub-Industry: N/A
- Symbol: NYSE:GI
- CUSIP: N/A
- Web: www.endochoice.com
- 50 Day Moving Avg: $8.00
- 200 Day Moving Avg: $7.14
- 52 Week Range: $3.64 - $8.03
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.35
- P/E Growth: 0.00
- Net Margins: -90.67%
- Return on Equity: -130.29%
- Return on Assets: -60.59%
- Debt-to-Equity Ratio: 0.93%
- Current Ratio: 3.95%
- Quick Ratio: 3.09%
Frequently Asked Questions for EndoChoice Holdings (NYSE:GI)
What is EndoChoice Holdings' stock symbol?
EndoChoice Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "GI."
How were EndoChoice Holdings' earnings last quarter?
EndoChoice Holdings Inc (NYSE:GI) issued its earnings results on Wednesday, May, 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.13. The firm earned $18.46 million during the quarter, compared to the consensus estimate of $18.34 million. EndoChoice Holdings had a negative return on equity of 130.29% and a negative net margin of 90.67%. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.00) EPS. View EndoChoice Holdings' Earnings History.
Where is EndoChoice Holdings' stock going? Where will EndoChoice Holdings' stock price be in 2017?
3 equities research analysts have issued 12-month target prices for EndoChoice Holdings' shares. Their predictions range from $7.00 to $7.00. On average, they anticipate EndoChoice Holdings' stock price to reach $7.00 in the next year. View Analyst Ratings for EndoChoice Holdings.
Who are some of EndoChoice Holdings' key competitors?
Some companies that are related to EndoChoice Holdings include Partnership Assurance Group PLC (PA), Merck & Co. (MRK), AstraZeneca plc (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Alnylam Pharmaceuticals (ALNY), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), Catalent (CTLT), NMC Health PLC (NMC) and Cotiviti Holdings (COTV).
When did EndoChoice Holdings IPO?
(GI) raised $101 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch, William Blair and Stifel acted as the underwriters for the IPO.
How do I buy EndoChoice Holdings stock?
Shares of EndoChoice Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EndoChoice Holdings' stock price today?
MarketBeat Community Rating for EndoChoice Holdings (NYSE GI)MarketBeat's community ratings are surveys of what our community members think about EndoChoice Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of EndoChoice Holdings stock can currently be purchased for approximately $8.00.
Consensus Ratings for EndoChoice Holdings (NYSE:GI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||$7.00 (12.50% downside)|
Analysts' Ratings History for EndoChoice Holdings (NYSE:GI)
(Data available from 7/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/30/2016||William Blair||Reiterated Rating||Market Perform||N/A|
|8/4/2016||Stifel Nicolaus||Lower Price Target||Buy||$10.00 -> $7.00||N/A|
|8/4/2016||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral||N/A|
|3/24/2016||Bank of America Corporation||Downgrade||Neutral -> Underperform||$10.00||N/A|
Earnings History for EndoChoice Holdings (NYSE:GI)Earnings History by Quarter for EndoChoice Holdings (NYSE GI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/4/2016||Q116||($0.55)||($0.68)||$18.34 million||$18.46 million||View||N/A|
|3/3/2016||Q415||($0.58)||($0.53)||$19.05 million||$18.50 million||View||N/A|
|11/5/2015||Q315||($0.54)||($0.47)||$18.42 million||$18.40 million||View||N/A|
|8/6/2015||Q215||($0.85)||($0.60)||$17.59 million||$18.60 million||View||N/A|
Earnings Estimates for EndoChoice Holdings (NYSE:GI)
2017 EPS Consensus Estimate: ($2.00)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for EndoChoice Holdings (NYSE:GI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for EndoChoice Holdings (NYSE:GI)
Insider Ownership Percentage: 31.50%Insider Trades by Quarter for EndoChoice Holdings (NYSE:GI)
Institutional Ownership Percentage: 37.32%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/16/2016||Mark Gilreath||CEO||Buy||20,000||$5.06||$101,200.00|| |
|3/15/2016||Mark Gilreath||CEO||Buy||5,018||$5.02||$25,190.36|| |
|3/11/2016||David L Kaufman||Director||Buy||89,450||$4.81||$430,254.50|| |
|3/10/2016||David N Gill||CFO||Buy||2,000||$4.70||$9,400.00|| |
|3/10/2016||William R Enquist||Director||Buy||10,000||$4.74||$47,400.00|| |
|3/8/2016||J Scott Carter||Director||Buy||21,600||$4.72||$101,952.00|| |
|3/7/2016||David N Gill||CFO||Buy||5,000||$4.77||$23,850.00|| |
Headline Trends for EndoChoice Holdings (NYSE:GI)
Latest Headlines for EndoChoice Holdings (NYSE:GI)
|Comparing EndoChoice Holdings (GI) & Analogic Corporation (ALOG)|
www.americanbankingnews.com - July 20 at 9:14 AM
|Critical Contrast: EndoChoice Holdings (GI) & Analogic (ALOG)|
www.americanbankingnews.com - June 26 at 12:10 AM
|EndoChoice Holdings (GI) versus NxStage Medical (NXTM) Critical Contrast|
www.americanbankingnews.com - June 15 at 7:50 AM
|NxStage Medical (NXTM) versus EndoChoice Holdings (GI) Head-To-Head Review|
www.americanbankingnews.com - June 6 at 12:04 PM
|ENDOCHOICE HOLDINGS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting|
biz.yahoo.com - November 22 at 5:03 PM
|Boston Scientific Closes EndoChoice Acquisition - PR Newswire (press release)|
www.prnewswire.com - November 22 at 8:41 AM
|Boston Scientific Closes EndoChoice Acquisition|
finance.yahoo.com - November 22 at 8:41 AM
|ENDOCHOICE HOLDINGS, INC. Financials|
finance.yahoo.com - November 16 at 5:29 PM
|ENDOCHOICE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 8 at 12:08 AM
|Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice - PR Newswire (press release)|
www.prnewswire.com - November 4 at 10:05 PM
|Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice|
finance.yahoo.com - November 4 at 6:41 AM
|Boston Scientific Raises Full-Year Outlook|
www.wsj.com - October 27 at 9:52 AM
|4 Medical Device Stocks on a Bull Run this Earnings Season|
finance.yahoo.com - October 26 at 5:16 PM
|Boston Scientific Announces Results For Third Quarter 2016|
finance.yahoo.com - October 26 at 8:20 AM
|ENDOCHOICE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of EndoChoice Holdings, …|
finance.yahoo.com - October 8 at 9:49 AM
|ENDOCHOICE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of EndoChoice Holdings, Inc. (GI) Over the Proposed Sale of the Company to Boston Scientific Corporation|
finance.yahoo.com - October 8 at 9:49 AM
|Boston Scientific Commences Cash Tender Offer For All Shares Of EndoChoice For $8.00 Per Share In Cash|
finance.yahoo.com - October 7 at 10:11 AM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of EndoChoice Holdings, Inc. And Encourages Investors To Contact The Firm For Additional ...|
www.businesswire.com - October 1 at 4:46 PM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of EndoChoice Holdings ... - Business Wire (press release)|
www.businesswire.com - September 30 at 5:29 PM
EndoChoice Holdings (GI) Chart for Monday, July, 24, 2017